COVID-19 疫苗接种背景下的脑静脉血栓形成的临床评估：评估、管理和科学问题。
Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions.
机构信息
Department of Neurology, Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, NY, USA.
National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK; Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Liverpool, UK.
出版信息
J Neurol Sci. 2021 Aug 15;427:117532. doi: 10.1016/j.jns.2021.117532. Epub 2021 Jun 5.
BACKGROUND
Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of thrombosis with thrombocytopenia, frequently including cerebral venous thromboses (CVT), that has been described following vaccination with adenovirus vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2·S Johnson and Johnson (Janssen/J&J). The evaluation and management of suspected cases of CVT post COVID-19 vaccination are critical skills for a broad range of healthcare providers.
METHODS
A collaborative comprehensive review of literature was conducted among a global group of expert neurologists and hematologists.
FINDINGS
Strategies for rapid evaluation and treatment of the CVT in the context of possible VITT exist, including inflammatory marker measurements, PF4 assays, and non-heparin anticoagulation.
背景
疫苗诱导的免疫介导的血小板减少症或 VITT，是一种最近出现的罕见血栓伴血小板减少症现象，常包括脑静脉血栓形成（CVT），在接种腺病毒疫苗 ChAdOx1 nCOV-19（阿斯利康）和 Ad26.COV2·S Johnson and Johnson（Janssen/J&J）后已被描述。评估和管理 COVID-19 疫苗接种后疑似 CVT 病例是广泛的医疗保健提供者的关键技能。
方法
一组全球专家神经病学家和血液学家合作进行了全面的文献复习。
发现
在可能的 VITT 背景下，存在针对 CVT 的快速评估和治疗策略，包括炎症标志物测量、PF4 检测和非肝素抗凝。
Zotero 插件